Pomanda estimates the enterprise value of VERSUS ARTHRITIS at £28.2m based on a Turnover of £31.7m and 0.89x industry multiple (adjusted for size and gross margin).
versus arthritisEstimated Valuation
£0
Pomanda estimates the enterprise value of VERSUS ARTHRITIS at £0 based on an EBITDA of £-2.3m and a 6.85x industry multiple (adjusted for size and gross margin).
versus arthritisEstimated Valuation
£317.5m
Pomanda estimates the enterprise value of VERSUS ARTHRITIS at £317.5m based on Net Assets of £135.2m and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Versus ArthritisOverview
Versus Arthritis is a live company located in london, EC1A 4JQ with a Companies House number of 00490500. It operates in the other human health activities sector, SIC Code 86900. Founded in January 1951, it's largest shareholder is
unknown.
Versus Arthritis is a mature,
large sized company, Pomanda has estimated its turnover at
£31.7m with
healthy
growth in recent years.
Pomanda's financial health check has awarded Versus Arthritis a 4 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 4 areas for improvement. Company Health Check FAQs
Health Rating4out of 5
5 Strong
3 Regular
4 Weak
Size
annual sales of £31.7m, make it larger than the average company (£728.4k)
£31.7m - Versus Arthritis
£728.4k - Industry AVG
Growth
3 year (CAGR) sales growth of 8%, show it is growing at a similar rate (7.2%)
8% - Versus Arthritis
7.2% - Industry AVG
Production
with a gross margin of 38.6%, this company has a comparable cost of product (38.6%)
38.6% - Versus Arthritis
38.6% - Industry AVG
Profitability
an operating margin of -8.1% make it less profitable than the average company (5.2%)
-8.1% - Versus Arthritis
5.2% - Industry AVG
Employees
with 302 employees, this is above the industry average (18)
302 - Versus Arthritis
18 - Industry AVG
Pay Structure
on an average salary of £43.8k, the company has a higher pay structure (£26.5k)
£43.8k - Versus Arthritis
£26.5k - Industry AVG
Efficiency
resulting in sales per employee of £105.1k, this is more efficient (£45.8k)
£105.1k - Versus Arthritis
£45.8k - Industry AVG
Debtor Days
it gets paid by customers after 6 days, this is earlier than average (20 days)
6 days - Versus Arthritis
20 days - Industry AVG
Creditor Days
its suppliers are paid after 7 days, this is quicker than average (18 days)
7 days - Versus Arthritis
18 days - Industry AVG
Stock Days
it holds stock equivalent to 0 days, this is less than average (13 days)
0 days - Versus Arthritis
13 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 99 weeks, this is less cash available to meet short term requirements (126 weeks)
99 weeks - Versus Arthritis
126 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 23.6%, this is a similar level of debt than the average (22.4%)
23.6% - Versus Arthritis
22.4% - Industry AVG
VERSUS ARTHRITIS financials
EXPORT
Versus Arthritis's latest turnover from March 2024 is £31.7 million and the company has net assets of £135.2 million. According to their latest financial statements, Versus Arthritis has 302 employees and maintains cash reserves of £36.1 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Jul 2012
Jul 2011
Jul 2010
Jul 2009
Turnover
31,731,000
29,425,000
30,609,000
25,438,000
25,244,000
42,932,000
33,547,000
28,877,000
36,677,000
39,871,000
36,009,000
25,981,000
40,224,000
36,261,000
39,265,000
37,519,000
Other Income Or Grants
Cost Of Sales
19,486,642
18,376,483
19,493,187
16,730,044
16,132,755
27,934,638
21,125,868
17,621,040
22,871,677
24,812,709
22,322,287
15,676,465
23,408,836
20,813,893
21,906,941
Gross Profit
12,244,358
11,048,517
11,115,813
8,707,956
9,111,245
14,997,362
12,421,132
11,255,960
13,805,323
15,058,291
13,686,713
10,304,535
16,815,164
15,447,107
17,358,059
Admin Expenses
14,817,098
13,107,548
26,245,327
67,235,624
33,055,207
30,653,879
29,320,387
21,249,524
10,276,185
9,550,552
10,680,029
4,991,082
19,285,456
16,293,982
15,071,343
-7,690,029
Operating Profit
-2,572,740
-2,059,031
-15,129,514
-58,527,668
-23,943,962
-15,656,517
-16,899,255
-9,993,564
3,529,138
5,507,739
3,006,684
5,313,453
-2,470,292
-846,875
2,286,716
7,690,029
Interest Payable
Interest Receivable
Pre-Tax Profit
-873,000
-571,000
-14,757,000
-58,459,000
-23,887,000
-15,332,000
-16,680,000
-9,925,000
2,903,000
4,423,000
2,378,000
4,098,000
-2,399,000
-771,000
1,711,000
5,572,000
Tax
Profit After Tax
-873,000
-571,000
-14,757,000
-58,459,000
-23,887,000
-15,332,000
-16,680,000
-9,925,000
2,903,000
4,423,000
2,378,000
4,098,000
-2,399,000
-771,000
1,711,000
5,572,000
Dividends Paid
Retained Profit
-873,000
-571,000
-14,757,000
-58,459,000
-23,887,000
-15,332,000
-16,680,000
-9,925,000
2,903,000
4,423,000
2,378,000
4,098,000
-2,399,000
-771,000
1,711,000
5,572,000
Employee Costs
13,222,000
12,554,000
15,142,000
15,126,000
12,863,000
11,249,000
9,551,000
7,418,000
6,626,000
6,605,000
6,643,000
4,275,000
6,133,000
4,297,000
3,485,000
2,854,000
Number Of Employees
302
280
357
351
349
316
255
199
187
194
185
189
189
158
135
16
EBITDA*
-2,283,740
-1,841,031
-14,556,514
-57,897,668
-23,240,962
-15,214,517
-16,618,255
-9,822,564
3,697,138
5,859,739
3,355,684
5,541,453
-2,121,292
-506,875
2,577,716
7,983,029
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Jul 2012
Jul 2011
Jul 2010
Jul 2009
Tangible Assets
1,130,000
1,160,000
1,248,000
1,871,000
2,323,000
2,685,000
2,419,000
895,000
627,000
711,000
5,383,000
5,472,000
5,598,000
5,829,000
5,839,000
5,960,000
Intangible Assets
655,000
440,000
2,000
155,000
Investments & Other
118,464,000
122,837,000
148,123,000
161,844,000
99,643,000
162,900,000
163,779,000
173,729,000
149,990,000
148,390,000
131,431,000
119,006,000
100,315,000
100,032,000
87,864,000
65,951,000
Debtors (Due After 1 year)
Total Fixed Assets
120,249,000
124,437,000
149,373,000
163,870,000
101,966,000
165,585,000
166,198,000
174,624,000
150,617,000
149,101,000
136,814,000
124,478,000
105,913,000
105,861,000
93,703,000
71,911,000
Stock & work in progress
13,000
8,000
108,000
83,000
14,000
40,000
53,000
51,000
41,000
45,000
69,000
187,000
42,000
142,000
Trade Debtors
531,000
714,000
664,000
546,000
302,000
26,839,000
10,242,000
9,587,000
13,347,000
11,861,000
8,820,000
3,227,000
Group Debtors
Misc Debtors
20,016,000
19,712,000
18,870,000
13,972,000
14,334,000
755,000
2,125,000
769,000
656,000
615,000
1,182,000
590,000
4,243,000
3,832,000
3,418,000
2,790,000
Cash
36,094,000
28,658,000
41,367,000
57,970,000
79,366,000
34,558,000
51,980,000
35,722,000
19,129,000
20,716,000
15,682,000
16,969,000
14,492,000
14,025,000
16,325,000
19,544,000
misc current assets
total current assets
56,654,000
49,092,000
61,009,000
72,571,000
94,002,000
62,152,000
64,361,000
46,118,000
33,185,000
33,243,000
25,725,000
20,831,000
18,804,000
18,044,000
19,785,000
22,476,000
total assets
176,903,000
173,529,000
210,382,000
236,441,000
195,968,000
227,737,000
230,559,000
220,742,000
183,802,000
182,344,000
162,539,000
145,309,000
124,717,000
123,905,000
113,488,000
94,387,000
Bank overdraft
Bank loan
Trade Creditors
415,000
538,000
564,000
708,000
992,000
12,914,000
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
18,386,000
19,758,000
20,277,000
30,442,000
13,292,000
16,983,000
15,830,000
13,203,000
12,971,000
12,859,000
995,000
1,035,000
15,878,000
12,958,000
13,525,000
9,539,000
total current liabilities
18,801,000
20,296,000
20,841,000
31,150,000
14,284,000
16,983,000
15,830,000
13,203,000
12,971,000
12,859,000
995,000
13,949,000
15,878,000
12,958,000
13,525,000
9,539,000
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
21,521,000
24,357,000
33,250,000
20,809,000
provisions
495,000
376,000
516,000
29,000
29,000
338,000
138,000
749,000
442,000
665,000
544,000
259,000
80,000
79,000
78,000
71,000
total long term liabilities
22,942,000
24,733,000
33,766,000
20,838,000
29,000
338,000
138,000
749,000
442,000
665,000
544,000
259,000
80,000
79,000
78,000
71,000
total liabilities
41,743,000
45,029,000
54,607,000
51,988,000
14,313,000
17,321,000
15,968,000
13,952,000
13,413,000
13,524,000
1,539,000
14,208,000
15,958,000
13,037,000
13,603,000
9,610,000
net assets
135,160,000
128,500,000
155,775,000
184,453,000
181,655,000
210,416,000
214,591,000
206,790,000
170,389,000
168,820,000
161,000,000
131,101,000
108,759,000
110,868,000
99,885,000
84,777,000
total shareholders funds
135,160,000
128,500,000
155,775,000
184,453,000
181,655,000
210,416,000
214,591,000
206,790,000
170,389,000
168,820,000
161,000,000
131,101,000
108,759,000
110,868,000
99,885,000
84,777,000
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Jul 2012
Jul 2011
Jul 2010
Jul 2009
Operating Activities
Operating Profit
-2,572,740
-2,059,031
-15,129,514
-58,527,668
-23,943,962
-15,656,517
-16,899,255
-9,993,564
3,529,138
5,507,739
3,006,684
5,313,453
-2,470,292
-846,875
2,286,716
7,690,029
Depreciation
240,000
193,000
325,000
387,000
463,000
442,000
281,000
171,000
168,000
352,000
349,000
228,000
349,000
340,000
291,000
293,000
Amortisation
49,000
25,000
248,000
243,000
240,000
Tax
Stock
5,000
-100,000
25,000
83,000
-14,000
-26,000
-13,000
2,000
10,000
-4,000
-24,000
-118,000
145,000
-100,000
142,000
Debtors
121,000
892,000
5,016,000
-118,000
-12,958,000
15,227,000
2,011,000
-3,647,000
1,527,000
2,474,000
6,185,000
-426,000
411,000
414,000
628,000
2,790,000
Creditors
-123,000
-26,000
-144,000
-284,000
992,000
-12,914,000
12,914,000
Accruals and Deferred Income
-1,372,000
-519,000
-10,165,000
17,150,000
-3,691,000
1,153,000
2,627,000
232,000
112,000
11,864,000
-40,000
-14,843,000
2,920,000
-567,000
3,986,000
9,539,000
Deferred Taxes & Provisions
119,000
-140,000
487,000
-309,000
200,000
-611,000
307,000
-223,000
121,000
285,000
179,000
1,000
1,000
7,000
71,000
Cash flow from operations
-3,785,740
-3,318,031
-29,419,514
-40,996,668
-13,290,962
-29,074,517
-16,587,255
-5,623,564
2,057,138
15,360,739
-15,494,316
4,241,453
506,708
-1,631,875
6,042,716
14,661,029
Investing Activities
capital expenditure
-7,335,000
-3,067,000
3,092,000
-365,000
-8,341,000
-8,397,000
Change in Investments
-4,373,000
-25,286,000
-13,721,000
62,201,000
-63,257,000
-879,000
-9,950,000
23,739,000
1,600,000
16,959,000
12,425,000
18,691,000
283,000
12,168,000
21,913,000
65,951,000
cash flow from investments
4,373,000
25,286,000
13,721,000
-62,201,000
63,257,000
879,000
9,950,000
-23,739,000
-1,600,000
-16,959,000
-19,760,000
-21,758,000
2,809,000
-12,533,000
-30,254,000
-74,348,000
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
-2,836,000
-8,893,000
12,441,000
20,809,000
share issue
7,533,000
-26,704,000
-13,921,000
61,257,000
-4,874,000
11,157,000
24,481,000
46,326,000
-1,334,000
3,397,000
27,521,000
18,244,000
290,000
11,754,000
13,397,000
79,205,000
interest
cash flow from financing
4,697,000
-35,597,000
-1,480,000
82,066,000
-4,874,000
11,157,000
24,481,000
46,326,000
-1,334,000
3,397,000
27,521,000
18,244,000
290,000
11,754,000
13,397,000
79,205,000
cash and cash equivalents
cash
7,436,000
-12,709,000
-16,603,000
-21,396,000
44,808,000
-17,422,000
16,258,000
16,593,000
-1,587,000
5,034,000
-1,287,000
2,477,000
467,000
-2,300,000
-3,219,000
19,544,000
overdraft
change in cash
7,436,000
-12,709,000
-16,603,000
-21,396,000
44,808,000
-17,422,000
16,258,000
16,593,000
-1,587,000
5,034,000
-1,287,000
2,477,000
467,000
-2,300,000
-3,219,000
19,544,000
versus arthritis Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for versus arthritis. Get real-time insights into versus arthritis's credit score, group structure and payment trends.
Perform a competitor analysis for versus arthritis by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other large companies, companies in EC1A area or any other competitors across 12 key performance metrics.
Versus Arthritis currently has 14 directors.
The longest serving directors include
Professor Martijn Steultjens (Nov 2017) and
Mr Vincent Noinville (Dec 2019).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to versus arthritis.
versus arthritis Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for VERSUS ARTHRITIS. This can take several minutes, an email will notify you when this has completed.
versus arthritisCompanies House Filings - See Documents
